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NOTES 
 
Breast Cancer and Depression among Breast Cancer Survivors 
 
Breast cancer starts when cells in the breast begin to grow out of control. These cells usually 
form a tumor that can often be seen on an x-ray or felt as a lump. The tumor is malignant 
(cancer) if the cells can grow into (invade) surrounding tissues or spread (metastasize) to 
distant areas of the body. Risk factors for developing breast cancer include being female, 
obesity, lack of physical exercise, drinking alcohol, hormone replacement therapy during 
menopause, ionizing radiation, early age at first menstruation, having children late or not at all, 
older age, prior history of breast cancer, and family history1. Except for skin cancer, breast 
cancer is the most commonly diagnosed cancer and the second leading cause of cancer 
mortality in women. Currently, more than three million women are living with breast cancer in 
the United States2. Previous studies have illustrated breast cancer survival is determined by 
factors including age, ethnicity, comorbidity, socio-economic factors, stage of cancer at 
diagnosis, and treatment3-7.  
Depression (major depressive disorder or clinical depression) is a common but serious mood 
disorder. It causes severe symptoms that affect how you feel, think, and handle daily activities, 
such as sleeping, eating, or working. To be diagnosed with depression, the symptoms must be 
present for at least two weeks8. In fact, cancer and treatment-related symptoms can be major 
stressors in a patient with breast cancer who is undergoing treatment for the disease. 
Therefore, addressing the impact of breast cancer and its treatment on long-term outcomes is 
an important issue. Depression is a noticeably common mental health outcome among breast 
cancer survivors, and its hypothesized association with adverse survival in breast cancer 
patients has been of interest in the past decade. Studies estimated that about 10% to 25% of 
breast cancer patients experience depression, which is higher compared with matched control 
group9,10; 
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Previous Studies about Depression on Survival and Treatment Among Breast 
Cancer Patients 
 
1. Survival after Early-stage breast cancer of women previously treated for depression: A 
nationwide Danish cohort study. 
 
• Year:2017  
• Journal: Journal of Clinical Oncology  
• Sample Populaiton:45325 women with early breast cancer in Denmark from 1998 to 
2011(744 women had a previous hospital contact, 6068 treated with antidepressants.  
• Conclusion: Women previously treated for depression constitute a large subgroup of 
patients with breast cancer who are at risk for receiving nonguideline breast cancer 
treatment. Which probably contributes to poorer overall and breast cancer-specific 
survival.  
• Depression Identification:1. To capture the most severe) # hospital months before 
diagnosis of cancer (ICD-8) ;2. Treatment with depressants form 3 months before 
diagnosis of breast cancer and 3 years previously (Prescription Registry).  
• Results: 1.  Those with previous hospital contact for depression or who dad used 
antidepressants were likely to be older, have less education, live alone, have comorbid 
somatic disease, and have breast cancer in later canlerder year. 2.  More women who 
had antidepressants received only a biopsy and not surgery and were therefore more 
likely to have unknown tumor size, number of tumor -positive lymph nodes, and ER 
status.  3.Statistically significantly fewer women who had used antidepressants were 
allocated to guideline systemic adjuvant therapy.                                                                                                                                    
4. 80% previously treated for depression still use antidepressants after cancer diagnosis. 
23% who not, started to use after diagnosis of breast cancer.                                                                                                                                                                            
5. Women who had used antidepressants were not allocated to guideline breast cancer 
treatment (p<0.05, OR=1.14).   Previously hospital contact (OR=1.32, 95%CI (0.99,1.77)).                                                                                                                                               
6.There's no difference in term of survival among patients with and without depression, 
if they all received adjuvant treatment according to the guidelines.  
• Limitaion:1. Other conditions such as anxiety and pain might account for more than 
25 % of prescribed antidepressants.   2. Possible misclassification of breast cancer 
specific death.           
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2. The association of mood disorders with breast cancer survival: an investigation of linked 
cancer registration and hospital admission data for South East England. 
 
• Year: 2016  
• Journal: Psychology  
• Sample Population: 77173 patients diagnosed with breast cancer in South East England 
from 2000 to 2009(depression = 955). Of these patients, 422 had a prior record of a 
diagnosis of depression, and 533 had a new record of depression after the cancer 
diagnosis. 
• Conclusion: There is evidence that English breast cancer patients with depression and 
bipolar recorded in routine hospital data have worse overall survival than those without 
these mood disorders. 
• Depression Identification: Patients with a diagnosis of At least one depressive episode 
(ICD‐10 F32) and recurrent depressive disorder (ICD‐10 F33) where these were 
recorded within HES in the 3 years before and the year following the cancer diagnosis. 
Patients with a diagnosis of either a recurrent depressive disorder or a depressive 
episode were grouped together as ‘depression’, either a recurrent depressive disorder 
or a depressive episode were grouped together as ‘depression’. 
• Results: 1. A record of depression was a predictor of worse overall survival in breast 
cancer patients (adjusted HR = 1.33, 95% CI: 1.20–1.48, p < 0.001), while the effect of 
bipolar was not statistically significant (adjusted HR = 1.33, 95% CI: 0.97–1.82, 
p = 0.079). New recordings of depression and bipolar diagnoses following a cancer 
diagnosis appeared better predictors of overall survival than a prior history of either.                                                                                                                                                                    
2. patients with a record of depression before or following the breast cancer diagnosis 
had a higher risk of dying even after adjusting for age, ethnicity, deprivation, 
comorbidities, stage of disease and treatment (fully adjusted HR = 1.33, 95% confidence 
interval (CI): 1.20–1.48, p < 0.001). The timing of the onset of depression appeared to be 
important. Depression recorded prior to the cancer diagnosis had a high unadjusted 
hazard ratio of 2.29 (95% CI: 1.98–2.64, p < 0.001) (Table 2), but this reduced to 1.23 
(95% CI: 1.07–1.42, p = 0.005) after adjustment, with the main attenuating factors being 
age, comorbidity and stage. Depression after the cancer diagnosis, when no previous 
history of depression had been recorded, demonstrated a high hazard ratio of 1.69 (95% 
CI: 1.46–1.95, p < 0.001) but was less affected by adjustment (HR = 1.45, 95% CI: 1.25–
1.68, p < 0.001). 
• Limitation: 1. There were several tumor factors that were not available to include in the 
study, including estrogen receptor, progesterone receptor and HER‐2 status; 
performance status; or more detailed staging information. 
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3. Prospective association of depression with survival: a population-based cohort study in 
patients with newly diagnosed breast cancer  
 
 
• Year: 2014 
• Journal: Breast Cancer Research Treatment 
• Sample Population: 1646 eligible patients with invasive female breast cancer stages I-IV 
from 2004 to 2009(562 presented with depression symptoms, 260 of these patients met 
clinical levels of depression. 
• Conclusion: Depression is strongly associated with mortality in younger patients with 
early stage breast cancer. 
• Depression Identification: Patients were routinely assessed for emotional distress after 
cancer diagnosis but before treatment initiation. (Base on DSM-IV-TR criteria)  
• Results: 1. (Stage I-III) Depression on all-cause mortality (HR=1.54. p=0.024), and breast 
cancer-specific mortality (HR=1.51, p=0.084). Age did not moderate association between 
depression and mortality. 2. Depression has an impact on all-cause and cancer-specific 
mortality in patients with stage I and Stage II(HR=2-2.5).                                                                                                                                                                                                                           
3.  Age moderates the association between depression and all-cause mortality in 
patients with stage I breast cancer. Younger patients at the age of 45(HR=9.82) with a 
depression compared to non-depresses patients (HR=9.82, p= 0.002).   Mean age of 57 
(HR=3.69, p=0.007). 4. Analyses by tumor stage revealed that the effect of depression 
on mortality is mostly driven by patients with earlier stage breast cancer (stage I and 
Stage II).    
• Limitation: 1. The relative brief depression measure does not substitute for a diagnosis 
of depression based on a structured clinical interview. 
 
 
4. Poor physical factors predict time to additional breast cancer events and mortality in 
breast cancer survivors 
 
• Year: 2011 
• Journal: Psychology 
• Sample Population "Women with early stage breast cancer (n=2967) at 7 study sites 
between 1995 and 2000. Breast cancer diagnosis within the past 4 years of primary 
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operable invasive stage I (≥ 1 cm), II, or IIIA breast carcinoma; age 18–70 years at time 
of diagnosis; 
• Conclusion "Social support, optimism, hostility, and depression prior to randomization 
into a dietary trial were assessed. However, Except for hostility, none of the other 
psycho-social variables predicted either outcome.  
• Depression Identification: "Depression was assessed by the 8-item Center for 
Epidemiologic Studies Depression screen (α=0.73). A value ≥ 0.06 in the logarithmic 
scale suggests clinical levels of depressive symptoms and the possibility of diagnosable 
mood disorder. 
• Results: "Social support, optimism, hostility, and depression prior to randomization into 
a dietary trial were assessed. However, except for hostility, none of the other psycho-
social variables predicted either outcome." 
 
 
5. Psychosocial factors and survival of young women with breast cancer: a population-
based prospective cohort study 
 
• Year: 2008 
• Journal: Journal of Clinical Oncology 
• Sample Population: A population-based sample of 708 Australian women diagnosed 
before age 60 years with nonmetastatic breast cancer was observed for a median of 8.2 
years. 73(3%) of these patients (HADs)were defined as with depression. 
• Conclusion: There were no statistically significant associations between any of the 
measured psychosocial factors and distant disease-free survival or overall survival from 
the adjusted analyses. The findings do not support the measured psychosocial factors 
being an important influence on breast cancer outcomes. 
• Depression Identification: Depression and anxiety, coping style, and social support were 
assessed at a median of 11 months after diagnosis using a face-to-face interview-
participants were administered epidemiologic questionnaires. 
• Results: 1. Greater anxious preoccupation was associated with younger age at diagnosis 
(P = .03), higher tumor grade (P = .02), and greater number of involved axillary nodes (P 
= .008).   2.Because the prevalence of probable depression (HADS score of > 10) was low 
(3%), analysis was repeated by, dichotomizing the HADS score at a cut point of 8 
(possible or probable depression v depression unlikely), and the results did not change 
substantially (data not shown). 
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6. Effect of depression on diagnosis, treatment, and survival of older women with breast 
cancer 
 
• Year: 2004 
• Journal: Journal of American Geriatric Society 
• Sample Population: Women aged 67 to 90 diagnosed with breast cancer between 1993 
and 1996 included in the SEER Medicare linked database. (N=24696, 7.5% with prior 
depression). 
• Conclusion: Women with a recent diagnosis of depression are at greater risk for 
receiving nondefinitive treatment and experience worse survival after a diagnosis of 
breast cancer, but difference in treatment do not explain the worse survival. 
• Depression Identification :2 years before breast cancer diagnosis (identified by ICD-9-CM 
code). 
• Results: 1. The women with a prior diagnosis of depression were on average older, more 
likely to be non-Hispanic white, less likely to be married, likely to have more comorbid 
illnesses. 2. There were no differences in tumor size at diagnosis in women with or 
without a prior diagnosis of depression. After controlling doctor visits, a diagnosis of 
depression was associated with increased size.                                                                             
3. Women with a history of depression were significant less likely to receive standard 
cancer treatment. 4 Receipt of definitive treatment did not appear to mediate this 
increased risk of death associated with depression. 
• Limitation: Only included women with breast cancer diagnosed at the age of 67 years or 
older, limiting the generalizability of result. 
 
 
 
7. Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: 
Analysis of Multiple Variables 
 
• Year: 2004 
• Journal: Journal of Clinical Oncology 
• Sample Population: 397 women diagnosed with breast cancer at participating University 
of Toronto teaching hospitals between1991 and 1996 (younger than 75, with T1 to T3, 
N0/N1, M0 breast cancer. 
• Conclusion: health-related quality of life (HRQOL) and psychosocial status at diagnosis 
and 1 year later are not associated with medical outcome in women with early-stage BC. 
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• Depression Identification: Based on self-report questionaire to identify distress status. 
• Results: Little convincing evidence was found that HRQOL or the psychosocial variables 
studied have important associations with distant disease-free survival (DDFS) or overall 
survival (OS) in women with newly diagnosed locoregional breast cancer.  
• Limitation: 1. measure of mood (POMS) provides scores for depression and anxiety, 
these scores are not intended to be measures of clinical depression or anxiety.                        
2.  Physiologic, compliance-related mechanisms, or social support in this research.                                                                     
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Initial Analysis Plan 
 
Outline: 
• Purpose 
1. To determine whether getting depression is associated with urban-
rural/Appalachia-non-Appalachia status among breast cancer survivors; 
2. To determine whether diagnosed with depression is associated with breast 
cancer treatment; 
3. To examine the association between depression treatment and urban-
rural/Appalachia-non-Appalachia status among breast cancer survivors 
diagnosed with depression; 
4. To find whether depression predicts worse survival among breast cancer 
survivors. 
• Data source: The Kentucky Cancer Registry (KCR) linked data, American Community 
Survey (ACS) census tract file. 
• Study population 
• Key variables 
1. Depression Status (yes or no) 
2. Treatment of depression 
3. Cancer survival 
4. Cancer treatment 
5. Rural/urban status 
6. Appalachia-Non-Appalachia status 
• Other independent variables 
• Statistical analysis: Chi-square; Logistic Regression; Cox Regression Model 
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Selection Criterion 
• Cancer cases: First Primary female breast cancer survivors age >=20, diagnosed at 2007-
2011; 
• Claims Data: Linked medicare, Medicaid, and private insurance claims data, 2006-2013; 
• Continuous enrollment: Not required yet. Indicator variable which indicates enrollment is 
needed, including 12 months prior, 12 months after.  
• Claims to define depression: 13 months (Month at the cancer diagnosis and 12 months 
after the diagnosis). 
• The current plan is to include all patients who had depression after cancer diagnosis from 
claims; for these without depression, only include patients who had continuous coverage. 
Variables and definitions 
Depression status (Yes or no Identified by ICD-9-CM code): 
. Major depressive disorder, single episode:296.20, 296.21,296.22,296.23,296.24, 
296.25,296.26; 
. Major depressive disorder, recurrent episode:296.30, 296.31, 296.32,296.33,296.34, 
296.35, 296.36; 
. Depressive type psychosis: 298.0; 
. Neurotic depression: 300.4; 
. Adjustment disorder with depressed mood: 309.0; 
. Prolonged depressive reaction: 309.1; 
. Depressive disorders, not classified: 311.0. 
Depression status will be calculated for both prior cancer diagnosis and after cancer 
diagnosis. Psychotherapy (Based on the following code to identify whether patients 
received Psychotherapy or not). 
❖ Revenue center codes: This only works for Medicare data (output file only) 
0114(Private medical or general-psychiatric) 
0124(Semi-private 2 bed (medical or general)-psychiatric) 
0134(Semi-private 3 and 4 beds-psychiatric) 
0144(Private (deluxe)-psychiatric) 
0154(Room & Board ward (medical or general)-psychiatric) 
0204(Intensive care-psychiatric); 
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❖ Provider specialty: The codes are different by claims sources 
o Medicare—NCH, DME hcfaspec 
26(Psychiatry) 
27(Geriatric psychiatry) 
62(Psychologist) 
68(Clinical psychologist) 
86(Neuropsychiatry); 
o Medicaid- PROV_SPEC 
011 - Psychiatric 011 - Psychiatric 
112 - Psychologist 112 - Psychologist 
339 - Psychiatrist 339 - Psychiatrist 
899 - Psychologist Group 899 - Psychologist Group 
o Humana- Provider Spcty 
103T00000X 103T00000X Psychologist 
103TA0400X 103TA0400X Psychologist Addiction-Substance Use 
103TA0700X 103TA0700X Psychologist Adult Development & Aging 
103TB0200X 103TB0200X Psychologist Behavioral 
103TC0700X 103TC0700X Psychologist Clinical 
103TC1900X 103TC1900X Psychologist Counseling 
103TC2200X 103TC2200X Psychologist Child, Youth & Family 
103TE1000X 103TE1000X Psychologist Educational 
103TE1100X 103TE1100X Psychologist Exercise & Sports 
103TF0000X 103TF0000X Psychologist Family 
103TF0200X 103TF0200X Psychologist Forensic 
102L00000X 102L00000X PSYCHOANALYST 
103G00000X 103G00000X Neuropsychologist 
103GC0700X 103GC0700X Neuropsychologist Clinical 
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103TH0100X 103TH0100X Psychologist Health 
103TM1700X 103TM1700X Psychologist Men & Masculinity 
103TM1800X 103TM1800X Psychologist Mental Retardation & Dev 
103TP0814X 103TP0814X Psychologist Psychoanalysis 
103TP2700X 103TP2700X Psychologist Psychotherapy 
103TP2701X 103TP2701X Psychologist Psychotherapy, Group 
103TR0400X 103TR0400X Psychologist Rehabilitation 
103TS0200X 103TS0200X Psychologist School 
103TW0100X 103TW0100X Psychologist Women 
163WP0808X 163WP0808X Reg Nurse Psych/Mental Health 
163WP0809X 163WP0809X Reg Nurse Psych/Mental Health-Adult 
167G00000X 167G00000X Licensed Psychiatric Technician 
1835P1300X 1835P1300X Pharmacist Psychopharmacy 
2084A0401X 2084A0401X Psychiatry & Neurology Addiction Medicin 
2084B0002X 2084B0002X BARIATRIC MEDICINE 
2084D0003X 2084D0003X DIAGNOSTIC NEUROIMAGING 
2084F0202X 2084F0202X Psychiatry & Neurology Forensic Psychiat 
2084N0400X 2084N0400X Psychiatry & Neurology 
2084N0402X 2084N0402X Psychiatry & Neurology Child Neuro 
2084N0600X 2084N0600X Psychiatry & Neurology Clinical Neurophy 
2084P0005X 2084P0005X Psychiatry & Neurology Neurodevelopment 
2084P0015X 2084P0015X PSYCHOSOMATIC MEDICINE 
2084P0800X 2084P0800X Psychiatry & Neurology Psychiatry 
2084P0802X 2084P0802X Psychiatry & Neurology Addiction Psych 
2084P0804X 2084P0804X Psychiatry & Neurology Child & Adolesc 
2084P0805X 2084P0805X Psychiatry & Neurology Geriatric Psych 
2084P2900X 2084P2900X Psychiatry & Neurology Pain Medicine 
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2084S0010X 2084S0010X Psychiatry & Neurology Sports Medicine 
2084V0102X 2084V0102X Psychiatry & Neurology Vascular Neurolog 
273R00000X 273R00000X Psychiatric Unit 
283Q00000X 283Q00000X Psychiatric Hospital 
323P00000X 323P00000X Psychiatric Residential Treatment Fac 
363LP0808X 363LP0808X Nurse Practitioner Psych/Mental Health 
364SP0808X 364SP0808X Clinical Nurse Spec Psych/Mental 
364SP0809X 364SP0809X Clinical Nurse Spec Psych/Mental Adult 
364SP0810X 364SP0810X Clin Nurse Spec Psych/Mental Child-Fam 
364SP0811X 364SP0811X Clin Nurse Spec Psych/Mental Chron Ill 
364SP0812X 364SP0812X Clin Nurse Spec Psych/Mental Community 
364SP0813X 364SP0813X Clin Nurse Spec Psych/Mental Geropsych 
 
oAnthem-- HCIProvSpec 
26 psychiatry; 
 
❖ CPT codes:  
90804–90829  
90845: Under Psychotherapy for Crisis Services and Procedures. 
90847: Family psychotherapy (conjoint psychotherapy) (with patient present) 
90849: Multiple-family group psychotherapy 
90853: Group psychotherapy (other than of a multiple family group) 
90857: Interactive group psychotherapy 
90865: Under Other Psychiatric Services or Procedures. 
90870: Under Other Psychiatric Services or Procedures 
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G0409: Social work and psychological services, directly relating to and/or furthering the 
patient's rehabilitation goals, each 15 minutes, face-to-face; individual (services provided by a 
corf-qualified social worker or psychologist in a corf). 
G0410: Group psychotherapy other than of a multiple-family group, in a partial hospitalization 
setting, approximately 45 to 50 minutes 
G0411: Interactive group psychotherapy, in a partial hospitalization setting, approximately 45 
to 50 minutes. 
❖ Antidepressant Usage (Identified by using National Drug Codes) 
 
Variables included:  
o Depression status 
o County 
o Census Tract 
o Race 
o Smoking status (both kcr and augmented) 
o Marital Status 
o County Beale code 
o Urban/Rural status 
o Insurance Type 
o Appalachian status 
o Age at diagnosis 
o Year of Diagnosis 
o Diagnostic Confirmation 
o Class of Case 
o ER, PR and HER2 status (csfactor1-16  
http://web2.facs.org/cstage0205/breast/Breastschema.html) 
o Best Stage 
o Tumor Size 
o Grade 
o Histology code 
o Behavior code 
o Sequence number 
o First course treatment (FstTrtCompCode) 
o Surgery code (RXSummSurgPrimSite) 
o Radiation Therapy: Yes or no (both KCR and augmented, same for chemo, horm and surg) 
o Chemotherapy: Yes or no 
o Hormonal Therapy: Yes or no 
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o Carlson Comorbidity Index score (CCI, if do not have 12 months continuous enroll and no 
claims information then consider as missing) 
o Survival status(vitalstat) 
o Follow-up time(survival_month) 
o County education and below poverty status  
Index: 
o 14 months continuous enroll: 1 month prior to 12 months after 
o 13 months continuous enroll: month of diagnosis to 12 months after 
o 12 months continuous enroll: 12 months prior cancer diagnosis 
o Subsequent cancer within 1 year 
o Smoking 12 months: capture smoking status using claims 12 months prior cancer diagnosis 
o Smoking 25 months: capture smoking status using claims 12 months prior and 12 months 
after 
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Breast Cancer Guideline Treatment Algorithm 
 
The treatment available in KCR: 
Surgery, Chemotherapy, Radiation, Immunotherapy, Hormone therapy, except Surgery, most 
other therapy known as Yes or NO with a starting date. 
Stage 0:  
      Main treatment (one of the following) 
• Lumpectomy + followed irradiation +hormone therapy  
• Mastectomy  
Stage I&II: 
       Main treatment (one of the following) 
• Lumpectomy + followed irradiation 
• Mastectomy. 
       Additional treatment 
• If patients have hormone receptor-positive (ER-positive or PR-positive) breast cancer, 
hormone therapy is included as standard care, and whether to receive chemotherapy 
depends on genomic analysis of the tumor (such as OncotypeDX). Since OncotypeDX is 
not available in standard KCR data, hormone therapy will be considered as standard 
care for ER, PR positive.  
• If the cancer is HER2-positive, treatment with trastuzumab (Immunotherapy) should be 
given.  
• If the cancer is not hormone receptor-positive, chemotherapy is given. 
Stage III: 
       Main treatment (one of the following) 
• Begin with any neoadjuvant therapy {Chemotherapy, and/or hormone therapy, and/or 
trastuzumab (immunotherapy), followed with lumpectomy/mastectomy, followed 
radiation 
• Begin with surgery. Followed with Mastectomy + adjuvant chemotherapy, and/or 
hormone therapy, and/or trastuzumab (immunotherapy). 
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      Additional treatment 
• If patients have hormone receptor-positive (ER-positive or PR-positive, HER2 negative) 
breast cancer, hormone therapy is included as standard care. 
• If the cancer is HER2-positive, treatment with trastuzumab (Immunotherapy) should be 
given.  
Stage IV: 
• Hormone receptor-positive and HER2 negative cancers: hormone therapies are used for 
as long as possible before chemotherapy is introduced 
• HER2-positive cancers: Trastuzumab/Herceptin (Immunotherapy is given along with 
chemothrepy) 
• Hormone receptor-negative cancers: Chemotherapy is the main treatment. 
• How about surgery or radiation? 
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SAS CODES 
Creating Formats for Categorical Variables 
proc format lib=out.formats; 
value appalf 
      0="Non-Appal"  
      1="Appal"; 
value smokerf 
      0="Non-smoker" 
   1='Smoker' 
   9='Unknown'; 
value stagef 
      0="Stage 0" 
   1='Stage I' 
   2="Stage II" 
   3="stage III" 
   4="Stage IV" 
   9='Unknown,N/A'; 
value seqcasef 
      0="No" 
   1="Yes"; 
value indicatorf 
      0="No" 
   1="Yes" 
      9='Unknown'; 
value treatclaimf 
      1='Yes'; 
value treatkcrf 
      1='Yes'; 
value chalsonf 
      -1='Missing' 
   0="0" 
   1="1" 
   2=">=2"; 
value hormonef 
      -1='Missing' 
      1='Positive/Elevated' 
      2='Negative' 
   9='Unknown'; 
value tumorsizef 
      -1='Missing' 
   1="<2" 
   2="2-<5" 
   3=">=5" 
      9='Unknown,N/A'; 
value agef 
      1='21-49' 
   2='50-65' 
   3='65-74' 
   4='75+'; 
  
value diagconf 
      1='Histology' 
   2='Imaging/Clinical' 
   9='Unknown'; 
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value $ firsttreatmentf 
      0='No Definitive Therapy or Surgery at Regional and/or Distant Sites 
only' 
      1='Surgery at Primary Site Only' 
      2='Chemotherapy Only' 
      3='Surgery at Primary Site/Chemotherapy' 
      4=' Radiation Therapy Only' 
      5='Surgery at Primary Site/Radiation Therapy' 
      6='Chemotherapy/Radiation Therapy' 
      7='Surgery at Primary Site/Chemo/Radiation Therapy' 
      8='Other Therapy Only' 
      9='Surgery at Primary Site/Other Therapy' 
      10='Chemotherapy/Other Therapy' 
      11='Surgery at Primary Site/Chemo/Other Therapy' 
      12='Radiation/Other Therapy' 
      13='Surgery at Primary Site/Radiation/Other Therapy' 
      14='Chemo/Radiation/Other Therapy' 
      15='Surgery at Primary Site/Chemo/Radiation/Other Therapy' 
      64='Unknown if or what therapy received'; 
value gradef 
      1='Well' 
   2='Moderate' 
   3='Poorly/Undifferentiated' 
      9='Unknown'; 
value maritalf 
      1='Married' 
   2='Never Married' 
   3='Separated/Divorced/Widowed' 
      9='Unknown'; 
value metrof 
      0='Non-metro' 
   1='Metro'; 
value pcharlsonf 
      -1='Missing' 
   0="0" 
   1="1" 
   2=">=2"; 
value racef 
      1='White' 
   2='Non-white' 
   9='Unknown'; 
value surgerytypef 
      0='NO' 
   1='Mastectomy' 
   2='Lumpectomy' 
      9='Unknown'; 
value urbanf 
      1='Urban' 
   0='Rural'; 
value vitalstatf 
      0='Dead' 
      1='Alive'; 
value $ tobaccof 
      0="Non-smoker" 
   1='Smoker' 
   9='Unknown'; 
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value highschoolf 
      1='<65%' 
   2='65%-<75%' 
   3='75%-<85%' 
      4='>=85%' 
      9='Unknown'; 
value povertyf 
      1='<5%' 
   2='5%-<10%' 
   3='%10-<20%' 
   4='>=20%' 
      9='Unknown'; 
value newmetrof 
      1='Metro' 
   2='Rural' 
   3='Isolated'; 
value stagegrpf 
      0='Stage 0' 
      1='Stage I&II' 
   2='Stage III&IV' 
   9='Unknown,N/A'; 
value cancertreatmentf 
      0='No' 
   1='Yes' 
   9='unknown'; 
value depressionf 
      0='No depression' 
      1='Pre&Pro depresion' 
   2='Pre depression only' 
   3='Post depression only' 
   9='Unknown'; 
value insurancef 
      0='No insurance' 
   1="Medicare" 
   2='Medicaid/Other Public' 
   3='Private insurance' 
   9='Unknown'; 
run; 
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Format Assignment 
 
options fmtsearch=(in.formats); 
 
data in.breast_capstonewithformat; 
set in.breast_capstone; 
format appal appalf. 
       AUGMENTED_FINALSMOKE_12M smokerf. 
    AUGMENTED_FINALSMOKE_25M smokerf. 
    STAGE stagef. 
    CENT_TIME_A  indicatorf. 
    CENT_TIME_B  indicatorf. 
    CHEMO_AUGMENTED indicatorf. 
    CHEMO_KCR treatkcrf. 
    CHARLSONGRP chalsonf. 
    ER hormonef. 
    PR hormonef. 
    HER2  hormonef. 
    TUMORSIZE tumorsizef. 
    DEPRESSION_STATUS indicatorf. 
    DEP_TIME_A indicatorf. 
    DEP_TIME_B indicatorf. 
    DIAGAGEGRP agef. 
    DIAGCONFIRMGRP diagconf. 
    DRUG_TIME_A indicatorf.    
       DRUG_TIME_B indicatorf.   
       ENROLL_14MON indicatorf. 
    FSTTRTCOMPCODE firsttreatmentf. 
    GRADE gradef. 
    HCPCS_TIME_A indicatorf. 
       HCPCS_TIME_B indicatorf. 
    psychotherapy_TIME_A indicatorf. 
       psychotherapy_TIME_B indicatorf. 
       HORM_AUGMENTED indicatorf. 
    HORM_KCR treatkcrf. 
    INDEX_1CLAIM indicatorf. 
    INDEX_ENROLL_12PRIOR indicatorf. 
       INDEX_ENROLL_13AFTER indicatorf. 
    INDEX_SUBSEQCASE indicatorf. 
    MARITALGRP maritalf. 
    METRO metrof. 
    PCHARLSONGRP pcharlsonf. 
       PROVD_TIME_A indicatorf. 
       PROVD_TIME_B indicatorf. 
    RACE racef. 
       RAD_AUGMENTED indicatorf. 
    RAD_KCR treatkcrf. 
    SURGERYTYPE surgerytypef. 
       SURG_AUGMENTED indicatorf. 
    SURG_KCR treatkcrf. 
    TOBACCO tobaccof. 
    TREAT_CENT indicatorf. 
       TREAT_HCPCS indicatorf. 
       TREAT_NDC  indicatorf. 
       TREAT_PROVD indicatorf. 
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       URBAN urbanf. 
    VITALSTAT vitalstatf. 
    highschool_or_more highschoolf. 
    below_poverty povertyf. 
    new_metro newmetrof.; 
run; 
 
 
 
 
 
 
Merging Census Tract Related Information with Primary Data 
PROC IMPORT OUT= WORK.census_tract  
            DATAFILE= "Z:\FeiTong Lei\Capstone\depression breast cancer\ 
depression breast cancer\tract,patient_id.xlsx"  
            DBMS=EXCEL REPLACE; 
     RANGE="Sheet1$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
RUN; 
 
 
libname in 'Z:\FeiTong Lei\Capstone\depression breast cancer\Data'; 
 
 
proc sort data=census_tract; 
by patient_id; 
run; 
 
proc sort data=in.breast_capstonewithformat; 
by patient_id; 
run; 
 
 
data in.allcases; 
merge census_tract in.breast_capstonewithformat; 
by patient_id; 
run; 
 
 
*****************MERGE INCOME AND EDUCATION INFORMATION BY CENSUS TRACT****; 
data capstone_allcases; 
set in.allcases; 
GEOID=cat(county,tract); 
run; 
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 libname ct 'Z:\FeiTong Lei\Medicare\Data\Census Tract\updated_datasets'; 
  data kyct2000; 
  set ct.kyct2000; 
  GEOID=cat(state,county,tract); 
  keep GEOID CTMED POV_TOT HS_TOT; 
  run; 
  proc sort data=capstone_allcases; 
  by GEOID; 
  run; 
  proc sort data=kyct2000; 
  by GEOID; 
  run; 
  data in.capstone_allcases; 
  merge capstone_allcases kyct2000; 
  by GEOID; 
  run; 
 
 
Data Cleaning and Data Management 
libname in 'Z:\FeiTong Lei\Capstone\depression breast cancer\Data'; 
options fmtsearch=(in.formats); 
 
data primarycases; 
set in.capstone_allcases; 
where centralsequencenumber in (0,1); 
run; 
 
proc format; 
value depressionf 
      0='No depression' 
      1='Pre&Pro depresion' 
   2='Pre depression only' 
   3='Post depression only' 
   9='Unknown'; 
run; 
 
    
*************Data complementary******; 
 
data primarycases; 
set primarycases; 
 
*********Creat a variable to indicate time recived 
psychotherapy before or after cancer diagnosis****; 
if cent_time_a=1 or hcpcs_time_a=1 or provd_time_a=1 then 
psychotherapy_time_a=1; 
 
if cent_time_b=1 or hcpcs_time_b=1 or provd_time_b=1 then 
psychotherapy_time_b=1; 
 
 
*******Creat a variable to indicate whethere psychotherapy recieved**; 
if Treat_cent=1 or treat_hcpcs=1 or treat_provd=1 then treat_psychotherapy=1; 
 
******Stage Group***********; 
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if beststagegrp ge 0 and beststagegrp lt 10 then stage = 0; 
else if beststagegrp ge 10 and beststagegrp lt 30 then stage=1; 
else if beststagegrp ge 30 and beststagegrp lt 50 then stage=2; 
else if beststagegrp ge 50 and beststagegrp lt 70 then stage=3; 
else if beststagegrp ge 70 and beststagegrp le 80 then stage=4; 
else if beststagegrp in (88,99) then stage=9; 
*********Early Stage or else****; 
if stage in (1,2) then stagegrp =1; 
else if stage in (3,4) then stagegrp=2; 
else if stage in(0) then stagegrp=0; 
else stagegrp =9; 
******tumorsize*********; 
if cstumorsize in (998,999) then tumorsize=9; 
else if cstumorsize ge 0 and cstumorsize lt 200 then tumorsize=1; 
else if cstumorsize ge 200 and cstumorsize lt 500 then tumorsize=2; 
else if cstumorsize in (990,991,992,996,997) then tumorsize=1; 
else if cstumorsize in (993,994,995) then tumorsize=2; 
else if cstumorsize ge 500 and cstumorsize le 989 then tumorsize=3; 
else tumorsize=-1; 
*********Charlson index***; 
if chrlson =0 then charlsongrp=0; 
else if chrlson = 1 then charlsongrp=1; 
else if chrlson ge 2 then charlsongrp=2; 
else charlsongrp=-1; 
***********ER Status******; 
if csfactor1 in (10) then ER=1; 
else if csfactor1 in (20) then ER=2; 
else if csfactor1 in (30,996,997,998,999) then ER=9; 
 
***********PR Status******; 
if csfactor2 in (10) then pr=1; 
else if csfactor2 in (20) then pr=2; 
else if csfactor2 in (30,996,997,998,999) then pr=9; 
 
******Hormone receptor status****; 
if er = 1 or pr =1 then Hormone_receptor =1; 
else if er =2 and pr=2 then Hormone_receptor=2; 
else Hormone_receptor=9; 
 
***********HER2 Status******; 
if csfactor15 in (10) then HER2=1; 
else if csfactor15 in (20) then HER2=2; 
else if csfactor15 in (30,996,997,998,999) then HER2=9; 
else HER2=-1; 
********Diagnostic age group****; 
if diagage gt 0 and diagage le 49 then DIAGAGEGRP=1; 
else if diagage ge 50 and diagage le 64 then diagagegrp=2; 
else if diagage ge 65 and diagage le 74 then diagagegrp=3; 
else if diagage ge 75 then diagagegrp=4; 
 
*******Diagconfirmation*****; 
if diagconfirm in (1,3) then diagconfirmgrp=1; 
else if diagconfirm in (2,4,5,6,7,8) then diagconfirmgrp=2; 
else if diagconfirm in (9) then diagconfirmgrp=9; 
 
*******Marital group*******; 
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if maritalstatus in (2,6) then maritalgrp=1; 
else if maritalstatus in (1) then maritalgrp=2; 
else if maritalstatus in (3,4,5) then maritalgrp=3; 
else if maritalstatus in (9) then maritalgrp =9; 
 
*********Prior Charlson score******; 
if pchrlson =0 then pcharlsongrp=0; 
else if pchrlson = 1 then pcharlsongrp=1; 
else if pchrlson ge 2 then pcharlsongrp=2; 
else pcharlsongrp= -1; 
 
********Race*******; 
if race1 in (1,3) then race =1; 
else if race1 in (2,4,5,6,8,10,15,16,96,98,97) then race=2; 
else if race1 in(99) then race =9; 
********Grade*******; 
if grade =1 then gradegrp=1; 
else if grade=2 then gradegrp=2; 
else if grade in(3,4 )then gradegrp=3; 
else gradegrp=9; 
******Surgery type******; 
if rxsummsurgprimsite in (0) then surgerytype =0; 
else if rxsummsurgprimsite ge 20 and rxsummsurgprimsite lt 30 then 
surgerytype =2; 
else if rxsummsurgprimsite ge 30 and rxsummsurgprimsite le 80  then 
surgerytype =1; 
else if rxsummsurgprimsite in (90,99) then surgerytype =9; 
******Below high school******; 
if hs_tot  ge 0 and hs_tot lt 65 then highschool_or_more=1; 
else if hs_tot ge 65 and hs_tot lt 75 then highschool_or_more=2; 
else if hs_tot ge 75 and hs_tot lt 85 then highschool_or_more=3; 
else if hs_tot ge 85 then highschool_or_more=4; 
else highschool_or_more=9; 
******Below Poverty*********; 
if pov_tot ge 0 and pov_tot lt 5 then below_poverty=1; 
else if pov_tot ge 5 and pov_tot lt 10 then below_poverty=2; 
else if pov_tot ge 10 and pov_tot lt 20 then below_poverty=3; 
else if pov_tot ge 20  then below_poverty=4; 
else below_poverty=9; 
********Metro,rural status****; 
if beale_code03 in (1,2,3) then new_metro=1; 
else if beale_code03 in (4,5,6) then new_metro=2; 
else if beale_code03 in (7,8,9) then new_metro=3; 
 
***********Time before cancer diagnosis(NO/Unknown)******; 
if dep_time_b ne 1 and index_enroll_12prior=1 then dep_time_b=0; 
else if dep_time_b ne 1 and index_enroll_12prior ne 1 then dep_time_b=9; 
 
if psychotherapy_time_b ne 1 and index_enroll_12prior =1 then 
psychotherapy_time_b=0; 
else if psychotherapy_time_b ne 1 and  index_enroll_12prior ne 1 then 
psychotherapy_time_b=9; 
 
if drug_time_b ne 1 and index_enroll_12prior =1 then drug_time_b=0; 
else if drug_time_b ne 1 and  index_enroll_12prior ne 1 then drug_time_b=9; 
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*******Time after cancer diagnosis(NO/Unknown)********; 
if dep_time_a ne 1 and index_enroll_13after=1 then dep_time_a=0; 
else if dep_time_a ne 1 and index_enroll_13after ne 1 then dep_time_a=9; 
 
 
if psychotherapy_time_a ne 1 and index_enroll_13after=1 then 
psychotherapy_time_a=0; 
else if psychotherapy_time_a ne 1 and index_enroll_13after ne 1 then 
psychotherapy_time_a=9; 
else if psychotherapy_time_a ne 1 then psychotherapy_time_a=9; 
 
 
if drug_time_a ne 1 and index_enroll_13after=1 then drug_time_a =0; 
else if drug_time_a ne 1 and index_enroll_13after ne 1 then drug_time_a=9; 
else if drug_time_a  ne 1 then drug_time_a =9; 
 
if psychotherapy_time_a=1 or drug_time_a=1 then depression_trt_after=1; 
else if psychotherapy_time_a=0 and drug_time_a =0 then 
depression_trt_after=0; 
else depression_trt_after=9; 
  
******depression status(no/unknown)***; 
if dep_time_b =0 and dep_time_a=0 then depression_status=0; 
else if depression_status ne 1 then depression_status=9; 
 
*********Cancer treatment********; 
if chemo_augmented=1 then chemo=1; 
else if chemo_augmented ne 1 and  index_enroll_13after=1 then chemo=0; 
else if chemo_augmented ne 1  and index_enroll_13after ne 1 then chemo=9; 
 
if horm_augmented=1 then horm=1; 
else if horm_augmented ne 1 and  index_enroll_13after=1 then horm=0; 
else if horm_augmented ne 1  and index_enroll_13after ne 1 then horm=9; 
 
if rad_augmented=1 then rad=1; 
else if rad_augmented ne 1 and  index_enroll_13after=1 then rad=0; 
else if rad_augmented ne 1  and index_enroll_13after ne 1 then rad=9; 
 
if surg_augmented=1 then surg=1;  
else if surg_augmented ne 1 and  index_enroll_13after=1 then surg=0; 
else if surg_augmented ne 1  and index_enroll_13after ne 1 then surg=9; 
 
 
*******Ceate a variable to indicate whether cancer treatment is 
appropriate****; 
*******For hormone receptor status******; 
/*if SURVIVAL_MONTH le 6 then appropriate_cancertreatment=-1; 
else if SURVIVAL_MONTH gt 6 then do;*/ 
 
if hormone_receptor =1 and horm=1 then horm_standard=1; 
 
else if hormone_receptor=1 and horm=0 then horm_standard=0; 
else if hormone_receptor=2 and horm=1 then horm_standard=0; 
else if hormone_receptor=2 and horm=0 then horm_standard=1; 
else horm_standard=9; 
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*******For stage 0*******; 
if stage=0 and surgerytype=1 then surg_standard=1; 
else if stage=0 and surgerytype=2 and rad=1 then surg_standard=1;   
else if stage=0 and surgerytype=2 and rad=0 then surg_standard=0; 
else if stage=0 and surgerytype=2 and rad=9 then surg_standard=9; 
else if stage=0 and surgerytype=0 then surg_standard=0; 
else if stage=0 and surgerytype=9 then surg_standard=9; 
 
if stage=0 and surg_standard=1 and horm_standard=1 then 
appropriate_cancertreatment=1; 
else if stage=0 and (surg_standard=0 or horm_standard=0) then 
appropriate_cancertreatment=0; 
else if stage=0 and surg_standard=1 and horm_standard=9 then 
appropriate_cancertreatment=9; 
else if stage=0 and surg_standard=9 and horm_standard=1 then 
appropriate_cancertreatment=9;  
 
***********For stage I&II********; 
if stage in (1,2) and surgerytype=0 then surg_standard=0; 
else if stage in (1,2) and surgerytype=1 then surg_standard=1; 
else if stage in (1,2) and surgerytype=2 and rad=1 then surg_standard=1;   
else if stage in (1,2) and surgerytype=2 and rad=0 then surg_standard=0; 
else if stage in (1,2) and surgerytype=2 and rad=9 then surg_standard=9; 
else if stage in (1,2) and surgerytype=9 then surg_standard=9; 
 
if stage in (1,2) and hormone_receptor=9 then chemo_standard=9;  
else if  stage in (1,2) and hormone_receptor=2 and chemo=1 then 
chemo_standard=1; 
else if  stage in (1,2) and hormone_receptor=2 and chemo=0 then 
chemo_standard=0; 
else if  stage in (1,2) and hormone_receptor=2 and chemo=9 then 
chemo_standard=9; 
else if  stage in (1,2) and hormone_receptor=1 then chemo_standard=1; 
else if  stage in (1,2) and hormone_receptor=9 then 
chemo_standard=9;*******To be discussed*****; 
 
 
if stage in (1,2) then do; 
if surg_standard=1 and horm_standard=1 and chemo_standard=1 then 
appropriate_cancertreatment=1; 
else if surg_standard=0 or horm_standard=0 or chemo_standard=0 then 
appropriate_cancertreatment=0; 
else if surg_standard=9 or horm_standard=9 or chemo_standard=9 then 
appropriate_cancertreatment=9; 
end;  
 
*********For stage III************; 
****Begin with neoneoadjuvant therapy***; 
 
if stage=3 then do; 
*if chemo=1 and surg=1 and datesurg1 < datechemo1 and surgerytype =2 then 
surg_standard=0; 
if surg=1 then surg_standard=1; 
else if surg=0 then surg_standard=0; 
else if surg=9 then surg_standard=9; 
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if chemo=0 then chemo_standard=0; 
else if chemo=1 then chemo_standard=1; 
else if chemo=9 then chemo_standard=9; 
 
if rad=0 then rad_standard=0; 
else if rad=1 then rad_standard=1; 
else if rad=9 then rad_standard=9; 
 
 
if surg_standard=1 and horm_standard=1 and chemo_standard=1 and 
rad_standard=1 then appropriate_cancertreatment=1; 
else if surg_standard=0 or horm_standard=0 or chemo_standard=0 or 
rad_standard=0 then appropriate_cancertreatment=0; 
else if surg_standard=9 or horm_standard=9 or chemo_standard=9 or 
rad_standard=9 then appropriate_cancertreatment=9; 
 
end; 
 
******For stage IV**********; 
if  stage =4 and hormone_receptor=2 and chemo=1 then chemo_standard=1; 
else if  stage =4 and hormone_receptor=2 and chemo=0 then chemo_standard=0; 
else if stage =4 and hormone_receptor=1 then chemo_standard=1; 
 
if stage=4 and horm_standard=1 and chemo_standard=1 then 
appropriate_cancertreatment=1; 
else if stage =4 and ( horm_standard=0 or chemo_standard=0) then 
appropriate_cancertreatment=0; 
else if stage=4 then appropriate_cancertreatment=9;  
 
********Stage unknown******; 
if stage=9 then appropriate_cancertreatment=9; 
 
label csfactor1='ER Status' 
      csfactor2='PR status' 
      csfactor3='HER2 Status' 
      dep_time_b='Depression diagnosed before cancer'; 
/*end;*/ 
 
*******new category of depression****; 
if dep_time_b=0 and dep_time_a=0 then depression=0; 
else if dep_time_b=1 and dep_time_a=1 then depression=1; 
else if dep_time_b=1 and dep_time_a=0 then depression=2; 
else if dep_time_b=0 and dep_time_a=1 then depression=3; 
else if dep_time_b =9 or dep_time_a=9 then depression=9; 
 
**********Insurance type************; 
if primarypayor in (1,2) then insurance_type=0; 
else if primarypayor in (10,99) then insurance_type=9; 
else if primarypayor in (60,61,62,63,64) then insurance_type=1; 
else if primarypayor in (31,35,65,66,67,68) then insurance_type=2; 
else if primarypayor in (20, 21) then insurance_type=3; 
 
 
format highschool_or_more highschoolf. new_metro newmetrof. stagegrp 
stagegrpf. gradegrp gradef.  
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depression_trt_after indicatorf. appropriate_cancertreatment 
cancertreatmentf.  diagagegrp agef. 
Hormone_receptor hormonef. chemo horm surg rad indicatorf. chemo_standard 
horm_standard surg_standard rad_standard indicatorf. depression depressionf. 
insurance_type insurancef.; 
run; 
 
 
data in.analysis; 
set primarycases; 
run; 
 
proc freq data=primarycases; 
table  appropriate_cancertreatment ; 
run; 
 
 
 
data depression; 
set primarycases; 
where depression ^in (9) and stage ^ in (0); 
run; 
 
 
proc freq data=fullenrollment; 
table appropriate_cancertreatment  ; 
run; 
 
 
Comparison between Patients Group Based on Depression Status 
libname in 'C:\Users\walala\Desktop\Capstone\depression breast cancer\Data'; 
options fmtsearch=(in.formats); 
 
ods pdf file='Z:\FeiTong Lei\Capstone\depression breast 
cancer\output\patients_character.pdf'; 
 
 
data depression; 
set in.analysis; 
where depression in (0,1,2,3)and stage in (1,2,3,4,9); 
format race racef.; 
run; 
 
data depression_a; 
set in.analysis; 
where dep_time_a in (0,1)and stage in (1,2,3,4,9); 
format race racef.; 
run; 
 
 
%macro sec(var); 
 
proc freq data=fullenrollment; 
table &var*depression/chisq; 
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where depression in (1,2); 
run; 
 
%mend; 
%sec(RACE); 
%sec(AUGMENTED_FINALSMOKE_12M); 
%sec(DIAGAGEGRP); 
%sec(APPAL); 
%sec(MARITALGRP); 
%sec(highschool_or_more); 
%sec(below_poverty); 
%sec(insurance_type); 
%sec(CHARLSONGRP); 
%sec(stage); 
%sec(gradegrp); 
%sec(Tumorsize); 
%sec(appropriate_cancertreatment); 
 
******Standard Treatment*****; 
%macro sec(var); 
 
proc freq data=in.fullenrollment; 
table &var*appropriate_cancertreatment/chisq; 
where appropriate_cancertreatment in (0,1);  
run; 
 
%mend; 
%sec(RACE); 
%sec(AUGMENTED_FINALSMOKE_12M); 
%sec(DIAGAGEGRP); 
%sec(APPAL); 
%sec(MARITALGRP); 
%sec(highschool_or_more); 
%sec(below_poverty); 
%sec(insurance_type); 
%sec(CHARLSONGRP); 
%sec(stage); 
%sec(gradegrp); 
%sec(Tumorsize); 
%sec(depression); 
 
 
 
 
**********Depression after Cancer*****; 
 
%macro sec(var); 
 
proc freq data=depression; 
table depression*&var/chisq; 
where depression in (0,3); 
 
run; 
%mend; 
%sec(AUGMENTED_FINALSMOKE_12M); 
%sec(APPAL); 
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%sec(new_metro); 
%sec(DIAGAGEGRP); 
%sec(MARITALGRP); 
%sec(STRATA); 
%sec(CHARLSONGRP); 
%sec(Hormone_receptor); 
%sec(HER2); 
%sec(STAGE); 
%sec(RACE); 
%sec(highschool_or_more); 
%sec(below_poverty); 
 
Logistic Regression and Cox Regression 
 
PROC LOGISTIC data=in.fullenrollment; 
class appropriate_cancertreatment(ref='Yes') DEP_TIME_B(REF='No') 
DEP_TIME_A(REF='No') depression_status(ref='No')depression(ref='No 
depression') AUGMENTED_FINALSMOKE_12M(ref="Non-smoker") APPAL (ref="Non-
Appal") 
      urban(ref='Urban') Metro(ref='Metro') DIAGAGEGRP(ref='21-49') 
MARITALGRP(ref='Married') RACE(ref='Non-white') STRATA (ref='1') 
CHARLSONGRP(ref="0") 
      PCHARLSONGRP(ref="0") ER(ref='Positive/Elevated') 
PR(ref='Positive/Elevated') GRADEgrp(ref='Poorly/Undifferentiated') 
HER2(ref='Positive/Elevated')STAGE(ref="Stage I")  
      TUMORSIZE(ref="<2") highschool_or_more(ref='>=85%') 
below_poverty(ref='<5%')Hormone_receptor(ref='Positive/Elevated') 
insurance_type(ref='Private insurance')/param=glm; 
model appropriate_cancertreatment= depression APPAL  highschool_or_more 
DIAGAGEGRP MARITALGRP  insurance_type  
                          CHARLSONGRP hormone_receptor; 
where appropriate_cancertreatment in (0,1); 
run; 
 
 
proc phreg data=fullenrollment; 
class depression_status(ref='No') depression(ref='No depression') dep_time_a 
(ref='No') dep_time_b(ref='No') AUGMENTED_FINALSMOKE_12M(ref="Non-smoker") 
APPAL (ref="Appal")surg_augmented (ref='Yes') 
      rad_augmented (ref='Yes') horm_augmented (ref='Yes') chemo_augmented 
(ref='Yes')  
      urban(ref='Urban') Metro(ref='Metro')  MARITALGRP(ref='Married') 
RACE(ref='Non-white') STRATA (ref='1') CHARLSONGRP(ref="0") 
      PCHARLSONGRP(ref="0") ER(ref='Positive/Elevated') 
hormone_receptor(ref='Positive/Elevated') GRADEgrp(ref='Well') 
HER2(ref='Positive/Elevated') 
      TUMORSIZE(ref="<2") highschool_or_more(ref='>=85%') 
below_poverty(ref='<5%')drug_time_a(ref='No') psychotherapy_time_a(ref='No') 
new_metro(ref='Metro') 
      appropriate_cancertreatment(ref='Yes') DIAGAGEGRP(ref='21-49') 
drug_time_a(ref='No') psychotherapy_time_a(ref='No')depression_trt_after 
(ref='No') STAGE(ref="Stage I") 
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      insurance_type(ref='Private insurance') /param=glm; 
model Survival_month*Vitalstat(1)= depression APPAL  AUGMENTED_FINALSMOKE_12M 
highschool_or_more  DIAGAGEGRP MARITALGRP  insurance_type  
                          STAGE CHARLSONGRP hormone_receptor gradegrp 
appropriate_cancertreatment  ;  
run; 
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OUTPUTS 
 
Table 1.  Patients Characteristics (n=6054) 
Factors 
No depression 
(n=5212) 
 
Pre&Post 
depression 
(n=246) 
 
Pre 
depression 
only 
(n=221) 
 
Post-
depression 
only (n=375) 
P-value  
 N Pct N Pct N Pct N Pct  
Race         0.3906 
White 4869 85.93 237 4.18 212 3.74 348 6.14  
Non-white 328 88.17 9 2.42 9 2.42 26 6.99  
Unknown 15 93.75 0 0.00 0 0.00 1 6.25  
Smoking Status         <.0001 
Non-smoker 2352 87.50 89 3.31 87 3.24 160 5.95  
Smoker 1797 82.54 121 5.56 94 4.32 165 7.58  
Unknown 1063 89.40 36 3.03 40 3.36 50 4.21  
Age at Diagnosis          
21-49 440 80.29 34 6.20 20 3.65 54 9.85 <.0001 
50-65 1042 80.90 85 6.60 62 4.81 99 7.69  
65-74 1920 86.96 78 3.53 73 3.31 137 6.20  
75+ 1810 90.05 49 2.44 66 3.28 85 4.23  
Appalachian Status         0.9966 
Non-Appal 3786 86.12 179 4.07 159 3.62 272 6.19  
Appal 1426 86.01 67 4.04 62 3.74 103 6.21  
Marital Status         0.0015 
Married 2558 87.84 110 3.78 97 3.33 147 5.05  
Never Married 348 82.27 25 5.91 18 4.26 32 7.57  
Separated/Divorced/Widowed 2133 84.91 100 3.98 103 4.10 176 7.01  
Unknown 173 83.57 11 5.31 3 1.45 20 9.66  
High school or more         0.8217 
<65% 1159 85.60 60 4.43 55 4.06 80 5.91  
65%-<75% 1324 86.09 59 3.84 52 3.38 103 6.70  
75%-<85% 1332 85.22 65 4.16 65 4.16 101 6.46  
>=85% 1383 87.31 62 3.91 49 3.09 90 5.68  
Unknown 14 93.33 0 0.00 0 0.00 1 6.67  
Below poverty         0.4112 
<5% 906 87.96 36 3.50 37 3.59 51 4.95  
5%-<10% 1317 85.91 73 4.76 53 3.46 90 5.87  
%10-<20% 1566 85.67 64 3.50 67 3.67 131 7.17  
>=20% 1409 85.50 73 4.43 64 3.88 102 6.19  
Unknown 14 93.33 0 0.00 0 0.00 1 6.67  
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Factors 
No depression 
(n=5212) 
 
Pre&Post 
depression 
(n=246) 
 
Pre 
depression 
only 
(n=221) 
 
Post-
depression 
only (n=375) 
     P-value  
Primary payer 
N Pct N Pct N Pct N Pct  
        <.0001 
No insurance 7 87.50 1 12.50 0 0.00 0 0.00  
Medicare 3722 86.56 168 3.91 145 3.37 265 6.16  
Medicaid/ Other Public  266 77.10 33 9.57 28 8.12 18 5.22  
Private insurance 1141 87.23 42 3.21 42 3.21 83 6.35  
Unknown 76 81.72 2 2.15 6 6.45 9 9.68  
Charlson Score         <.0001 
Missing 217 97.31 1 0.45 0 0.00 5 2.24  
0 3075 87.91 111 3.17 102 2.92 210 6.00  
1 1132 84.41 62 4.62 53 3.95 94 7.01  
>=2 788 79.44 72 7.26 66 6.65 66 6.65  
Stage         0.0032 
Stage I 2473 87.35 108 3.81 98 3.46 152 5.37  
Stage II 1560 84.23 87 4.70 65 3.51 140 7.56  
stage III 588 83.40 34 4.82 28 3.97 55 7.80  
Stage IV 348 90.39 9 2.34 16 4.16 12 3.12  
Unknown,N/A 243 86.48 8 2.85 14 4.98 16 5.69  
Grade         0.2868 
Well 1129 86.98 52 4.01 38 2.93 79 6.09  
Moderate 2172 85.92 101 4.00 96 3.80 159 6.29  
Poorly/Undifferentiated 1480 85.65 75 4.34 59 3.41 114 6.60  
Unknown 431 86.20 18 3.60 28 5.60 23 4.60  
Tumor Size (cm)         0.2088 
<2 4926 86.19 230 4.02 204 3.57 355 6.21  
2-<5 19 73.08 2 7.69 2 7.69 3 11.54  
>=5 2 66.67 1 33.33 0 0.00 0 0.00  
Unknown,N/A 265 85.48 13 4.19 15 4.84 17 5.48  
Standard Cancer Care         0.1485 
No 1523 86.05 69 3.90 79 4.46 99 5.59  
Yes 3256 85.93 161 4.25 122 3.22 250 6.60  
unknown 433 87.47 16 3.23 20 4.04 26 5.25  
 
 
 
 
 
 
FEITONG LEI 11/20/2018 
  
 
FEITONGLEI@GMAIL.COM 35 
 
 
Table 2. Standard Treatment (n=5559) 
Factors  
Nonguideline 
Treatment 
(n=1770) 
Guideline 
Treatment 
(n=3789) p- 
value 
N Pct N Pct  
Depression 
    
0.0586 
No depression 1523 31.8686 3256 68.13   
Pre/Post Depression 69 30 161 70.00   
Pre-depression only 79 39.3035 122 60.70   
Post-depression only 99 28.3668 250 71.63   
Race 
    
0.0566 
White 1655 31.8514 3541 68.15   
Non-white 115 32.7635 236 67.24   
Unknown 0 0 12 100.00   
Smoking Status 
    
<.0001 
Non-smoker 793 31.4932 1725 68.51   
Smoker 607 29.4517 1454 70.55   
Unknown 370 37.7551 610 62.24   
Age at Diagnosis 
    
<.0001 
21-49 77 14.6667 448 85.33  
 
50-65 227 18.7139 986 81.29  
 
65-74 535 26.1486 1511 73.85  
 
75+ 931 52.4507 844 47.55  
 
Appalachian Status 
    
0.5456 
Non-Appal 1285 31.6113 2780 68.39   
Appal 485 32.4632 1009 67.54   
Marital Status 
    
<.0001 
Married 677 24.681 2066 75.32   
Never Married 124 31.3131 272 68.69   
Separated/Divorced/Widowed 917 40.3432 1356 59.66   
Unknown 52 35.3741 95 64.63   
High school or more 
    
<.0001 
<65% 356 29.3245 858 70.68   
65%-<75% 516 36.9099 882 63.09   
75%-<85% 469 32.3671 980 67.63   
>=85% 425 28.581 1062 71.42   
Unknown 4 36.3636 7 63.64   
Below poverty 
    
0.0076 
<5% 270 27.9214 697 72.08   
5%-<10% 430 30.3672 986 69.63   
%10-<20% 575 34.2874 1102 65.71   
>=20% 491 32.9973 997 67.00   
Unknown 4 36.3636 7 63.64   
Primary payer 
    
<.0001 
No insurance 2 25.00  6 75.00  
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Table 2. Standard Treatment (n=5559) (Cont.) 
Factors 
Nonguideline 
Treatment 
(n=1770) 
Guideline 
Treatment 
(n=3789) 
p- value 
N Pct N Pct   
Medicare 1476 37.24  2487 62.76  
 
Medicaid/Other Public  90 27.61  236 72.39  
 
Private insurance 192 15.46  1050 84.54  
 
Unknown 10 50.00  10 50.00  
 
Charlson Score 
    
<.0001 
Missing 64 32.4873096 133 67.51   
0 905 27.8290283 2347 72.17   
1 419 34.0650407 811 65.93   
>=2 382 43.4090909 498 56.59   
Stage 
    
<.0001 
Stage I 900 32.9067642 1835 67.09   
Stage II 444 24.6119734 1360 75.39   
stage III 355 51.0057471 341 48.99   
Stage IV 71 21.9135802 253 78.09   
Grade 
    
<.0001 
Well 371 30.4597701 847 69.54   
Moderate 717 29.875 1683 70.13   
Poorly/Undifferentiated 541 32.9275715 1102 67.07   
Unknown 141 47.3154362 157 52.68   
Tumor Size (cm) 
    
0.3778 
<2 1725 31.7153889 3714 68.28   
2-<5 9 39.1304348 14 60.87   
>=5 2 66.6666667 1 33.33   
Unknown, N/A 34 36.1702128 60 63.83    
 
 
 
 
 
 
 
 
 
FEITONG LEI 11/20/2018 
  
 
FEITONGLEI@GMAIL.COM 37 
 
Table 3. Multivariable logistic regression to identify the association between 
depression status and nonguideline cancer treatment. 
 
Variables  OR 95% CI P-value 
Depression Status    0.2815 
Pre depression only 1.379 0.992 1.918  
Post depression only 0.964 0.736 1.263  
Pre & Post depression  1.041 0.751 1.441  
No Depression Ref    
Applachian Status    0.0269 
Applachian  1.232 1.024 1.482  
Non-Appalachian Ref    
Age at Diagnosis    <.0001 
50-65 1.239 0.915 1.677  
65-74 1.872 1.352 2.592  
75+ 5.929 4.252 8.266  
21-49 Ref    
Marital Status    0.0015 
Never Married 1.361 1.054 1.757  
Seperated/Divorced/Widowed 
1.294 1.125 1.489  
Unknown 1.275 0.858 1.894  
Married Ref    
High School or more    0.0002 
<65% 0.827 0.653 1.048  
65%-<75% 1.295 1.081 1.553  
75%-<85% 1.124 0.942 1.341  
Unknown 1.845 0.496 6.863  
>=85% Ref    
Primary payer    0.0078 
No insurance 1.887 0.352 10.127  
Medicare 1.474 1.144 1.9  
Medicaid/Other Public  1.734 1.245 2.413  
Unknown 1.845 0.496 6.863  
Private insurance Ref    
Charlson Score 
   
<.0001 
1 1.093 0.934 1.28  
>=2 1.58 1.325 1.884  
Missing 1.375 0.953 1.985  
0 Ref    
Stage 
   
<.0001 
Stage II 0.539 0.464 0.626  
Stage III 1.96 1.619 2.372  
Stage IV 0.386 0.285 0.522  
Stage I Ref 
  
 
Hormone Receptor 
   
<.0001 
Negative 2.762 2.349 3.247  
Positive Ref       
 
 
 
FEITONG LEI 11/20/2018 
  
 
FEITONGLEI@GMAIL.COM 38 
 
 
Figure 1. Survival curves in breast cancer patients grouped based on depression 
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Figure 2. Survival curves in breast cancer patients grouped based on 
Appalachian Status 
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Tables 4. Adjusted Cox hazard regression to identify the association between 
depression and survival. 
 
 
Variables  OR 95% CI P-value 
Depression Status    0.0003 
Pre depression only 1.23 0.97 1.56  
Post depression only 1.50 1.23 1.82  
Pre & Post depression  1.16 0.90 1.49  
No Depression Ref    
Applachian Status    0.0102 
Non-Appalachian 1.20 1.04 1.37  
Applachian  Ref    
Age at Diagnosis    <.0001 
50-65 1.15 0.88 1.50  
65-74 1.37 1.03 1.82  
75+ 2.59 1.95 3.44  
21-49 Ref    
Smoking Status    <.0001 
Smoker 1.38 1.23 1.55  
Unknown 1.23 1.07 1.40  
Non-smoker     
Marital Status    <.0001 
Never Married 1.57 1.29 1.91  
Seperated/Divorced/Widowed 1.24 1.10 1.40  
Unknown 1.10 0.85 1.43  
Married     
High School or more    0.0008 
<65% 1.38 1.15 1.65  
65%-<75% 1.30 1.12 1.51  
75%-<85% 1.33 1.14 1.54  
Unknown 0.79 0.32 1.93  
>=85%     
Primary payer    <.0001 
No insurance 4.53 1.42 14.49  
Medicare 1.45 1.14 1.84  
Medicaid/Other Public  1.82 1.37 2.42  
Unknown 1.81 1.35 2.43  
Private insurance Ref    
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Tables 4. Adjusted Cox hazard regression to identify the association between 
depression and survival (Cont.) 
 
 
Variables  OR 95% CI P-value 
Charlson Score    <.0001 
1 1.27 1.11 1.44  
>=2 1.90 1.68 2.16  
Missing 1.67 1.33 2.10  
0     
Stage    <.0001 
Stage II 1.86 1.61 2.15  
Stage III 3.24 2.77 3.80  
Stage IV 14.62 12.35 17.30  
Unknown 5.16 3.80 7.01  
Stage I Ref    
Hormone Receptor    <.0001 
Negative 1.45 1.27 1.66  
Unknown 2.17 1.71 2.74  
Positive Ref   <.0001 
Grade      
Moderate 1.41 1.19 1.67  
Poorly/Undifferentiate 1.70 1.42 2.04  
Unknown 1.77 1.44 2.17  
Well     
Standard Cancer Treatment    <.0001 
No 2.20 1.95 2.49  
Unknown 1.08 0.78 1.47  
Yes Ref      
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RESULTS 
 
Among the 6054 patients, 5212(86.1%) patients were not diagnosed with depression in both 
time periods, and 221(3.7%) patients had a depression diagnosis only within one year before 
the cancer diagnosis; meanwhile, 375(6.2%) patients had new recordings of depression after 
cancer diagnosis, and 246(4.1%) women both had depression diagnosis before and after cancer 
diagnosis. Table 1 presents the comparison of demographic characters and clinical information 
among the four groups. Compared with women who have not been diagnosed with depression, 
breast cancer patients who were identified as with depression during the baseline and follow-
up period were statistically significantly more likely to be smokers, younger, from 
Medicare/other public insurance, not in a state of marriage, and with more comorbid diseases. 
Though Appalachian showed a slightly larger percentage of being diagnosed with depression, 
the increase was not statistically significant (p-value=0.99).  
Table 2 displays the results of multivariable logistic regression. In the multivariable logistic 
regression analysis examining the influence of depression and Appalachian status on receiving 
nonguideline cancer treatment, 495 patients with unknown treatment information were 
excluded, and which resulted in 5559 eligible subjects in this analysis. 1770(31.8%) patients 
were defined as not receiving guideline treatment. After adjusting other variables that might 
impact the decision of treatment, no statistically significant association was found between 
depression and receiving nonguideline treatment(p-value=0.282), and patients only had pre-
diagnostic depression showed an increased but nonsignificant odds ratio (OR, 1.38; 95% CI, 
0.99-1.92) in receiving nonguideline treatment compared to patients without depression. 
Patients from Appalachian regions showed an increased association with receiving nonguideline 
treatment (OR, 1.23; 95% CI, 1.02-1.48). 
Survival curves obtained from the Kaplan–Meier method (Figure 1) shows that patients 
diagnosed with depression only within one year before cancer diagnosis had the worst survival 
(more explanation needed?) Table 3 shows the results from the Cox regression analysis, the 
adjusted effect of depression on survival among breast cancer patients were shown. The 
association between depression and mortality was statistically significant(p-value<.001). 
Patients with new recordings of depression after the cancer diagnosis had a significant risk for 
death (HR, 1.50; 95% CI, 1.23-1.82). However, increased but nonsignificant risks for death were 
shown in patients diagnosed with depression only within one year before cancer diagnosis (HR, 
1.23; 95% CI, 0.97-1.56) and patients had depression diagnosis in both periods (HR, 1.16; 95% 
CI, 0.90-1.49). Results also illustrated that patients received nonguideline cancer treatment 
showed a significantly higher adjusted hazard ratio (HR, 2.20; 95% CI, 1.95-2.49) than those 
received guideline treatment.  
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LESSONS LEARNED 
 
• Finish early: This allows ideas and designs to stew. Finishing earlier provides more time 
to explore details and revise potential errors. Though there’s some saying about the 
power of last-minute adrenalin-panic for increasing productivity, it’s much less stressed 
when projects were planned and conducted ahead. 
 
• Talk about the project. It’s important to communicate with others by expressing my own 
project. In this process, I realized what I knew and didn’t know about in this project, 
then I would search for relative information to learn those points I was not quite 
understand, and information I was missing helped me stay on track and discover new 
paths for research. Meanwhile, others may provide precious advice regarding this 
project. 
 
 
• Summarize and create a list of resources. At the beginning, I found myself going back 
again and again to read related papers and study their methods and results, which was 
time-consuming to search and find those papers. Then, I decided to summarize those 
papers briefly and put the summary in one single word document. Whenever I needed 
to get basic information from those papers, I simply used that file to guide me. 
 
• After half of the basic research is done, look for a really good summary of the field to 
reorient yourself. More broadly, make sure to take a breath and get perspective on your 
project and goals. 
 
 
• Most Importantly: 
It is ok to say“I don’t know and I am having some troubles”. There were times I was 
having a hard time coding or understanding, but I was afraid to express that and only 
spent time worrying, which resulted in delays of some tasks. Then I learned the 
important lesson of admitting “I don’t know and I may not on the right track”, which 
actually reflects the sense of responsibility as a member of a team-we should keep on 
communicating the process of projects and letting others know whether we fully 
understand what we are doing. 
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FINAL PAPER  
*Tables and Figures were put in the outputs section(page33-41) 
Influence of depression on treatment and survival: a population-based study in patients with 
breast cancer in Kentucky 
Abstract  
BACKGROUND 
Few prior studies have explored the impact of the combination of depression in two periods 
(before and after the cancer diagnosis) on guideline cancer treatment and survival among 
breast cancer survivors. With large area defined as Appalachian regions in Kentucky, the 
present study also aimed to find the disparity between Appalachian and non-Appalachian 
regarding developing depression and receiving standard cancer treatment. 
METHODS 
Kentucky Cancer Registry (KCR) data linked with Medicare, Medicaid, and private insurance 
claims data was used in this study. 6054 patients with primary invasive breast cancer aged 20 or 
older at the time of cancer diagnosis from 2007 to 2011 were included. 12 months before and 
13 months from cancer diagnosis were two time periods to searching for depression diagnosis 
in claims data. Multivariate logistic regression and multivariate Cox regression were separately 
performed to assess the effect of the combination of depression at two periods on patients’ 
receiving of guideline cancer treatment and overall survival. 
RESULTS 
There was no statistically significant association between depression and receiving 
nonguideline treatment(p=0.2815). Patients reside in the Appalachian area had a significantly 
higher risk of receiving nonguideline cancer treatment (odds ratio, 1.23; 95% CI, 1.02-1.48). 
Significant associations between depression and survival were found in patients with newly 
diagnosed depression diagnosis after cancer diagnosis (hazard ratio,1.50; 95% CI, 1.23-1.82). 
Increased but nonsignificant risks for death were also identified in patients with pre-diagnostic 
depression only or patients with a depression diagnosis in both periods. 
CONCLUSIONS  
Depression did not contribute to receiving nonguideline treatment among breast cancer 
patients, and Appalachian patients were statistically significantly more likely to receive 
nonguideline treatment. Patients with newly diagnosed depression after the cancer diagnosis 
had a significantly increased risk of death. 
KEYWORDS: depression, breast cancer, guideline cancer treatment, survival, Appalachian 
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INTRODUCTION 
Breast cancer is the most commonly diagnosed cancer except for skin cancer, and it also is  the 
second leading cause of cancer death in women. Currently, more than three million women are 
living with breast cancer in the United States1. Previous studies have illustrated breast cancer 
survival is influenced by factors including age, ethnicity, comorbidity, smoking status, 
socioeconomic factors, stage of cancer at diagnosis, and cancer treatment2-9.  
Depression is a noticeably common mental health outcome among breast cancer survivors, and 
its hypothesized association with adverse survival in breast cancer patients has been of interest 
in the past decade. Studies estimated that about 10% to 25% of breast cancer patients 
experience depression, which is higher compared with matched control group10,11; however,  
associations between depression and survival found by prior studies remained inconsistent. For 
most studies which determined depression status in breast cancer patients depended on self-
report questionnaires, the association between depression and survival has not been 
recognized12-16. Though some of these studies have illustrated the relationship between 
depression and survival17-19, the relatively brief depression measurement using questionnaires 
is limited compared to depression diagnosis based on systematic clinical consultations. By 
capturing depression based on clinical diagnosis, two large retrospective studies demonstrated 
breast cancer patients with depression had a higher likelihood of death20,21; however, both 
studies did not include covariates like lifestyle, socioeconomic factors, hormone receptor 
status. Several of these variables could predict higher mortality in breast cancer patients8,22-24.  
From a clinical perspective, we are also curious about whether patients with a depression 
diagnosis are a vulnerable patient group that received nonguideline cancer treatment, which 
also may lead to worse survival in breast cancer survivors. Two previous studies have reported 
depression as a negative predictor of receiving guideline cancer care25,26. However, one study 
only included elder patients who were 67 years old or older at the time of breast cancer 
diagnosis25, and another study conducted in Denmark only assessed the relationship between 
depression and adjuvant systemic therapy26.  
No prior studies have investigated the influence of combinations of depression in two time 
periods (before and after cancer diagnosis) on the survival and guideline treatments, which 
distinguishes breast cancer patients who were not depressed, who were diagnosed with 
depression only before cancer, who were diagnosed with depression only after cancer 
diagnosis, and who were depressed before and after cancer diagnosis, and this allows more 
detailed study on the influence of depression. Previous studies have investigated the effect of 
pre/post-diagnostic depression on the survival in breast cancer patients20,21. One of them 
explored the influence depending on the onset of depression separately20, and another only 
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compared the influence of pre-diagnostic depression and new recordings of depression after 
cancer daignosis21. 
The Kentucky Cancer Registry (KCR) data linked with Medicare, Medicaid, and private insurance 
administrative claims data were utilized in this study. Importantly, this study included records 
from privately insured patients, who continue to comprise the largest segment of US healthcare 
users, and few population-based studies in this field had been linked to private insurance claims 
data. Patients resided in Kentucky were obtained from this data. Kentucky has the highest 
cancer incidence and mortality rates in the U.S. There’re 54 counties defined as Appalachian in 
Kentucky, and many of these counties are identified as economically depressed, the most rural, 
and underserved communities in the U.S27. Cancer death rates in rural Appalachian counties in 
Kentucky were nearly 36% higher than in non-Appalachian urban areas nationwide. Of note, 
breast cancers were found at more advanced stages in women living in Appalachian states, and 
the 3- to 5-year survival rates for all cancers were lower compared with cases from urban non-
Appalachian communities28. Therefore, except for the primary objectives of examining the 
influence of depression on standard treatment and survival in breast cancer patients, we also 
conducted the study with a secondary focus on the Appalachian regions to explore whether 
there’re disparities between Appalachian areas and non-Appalachian areas. In conclusion, we 
hypothesized that: (1) depression is associated with receiving nonguideline cancer treatment in 
breast cancer patients; (2) depression predicts worse survival in breast cancer survivors; (3) 
Appalachian patients are more likely to experience depression and receive nonguideline cancer 
treatment. 
 
MATERIALS AND METHODS 
Data source 
Incident breast cancer cases were obtained from the Kentucky Cancer Registry (KCR), which is a 
member of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) 
program. The KCR data provide information about demographics, tumor characteristics, initial 
treatment, and survival of cancer patients. In this study, KCR data have been linked to 
Medicare, Medicaid, and private insurance administrative databases. These administrative 
databases consist of beneficiaries’ covered health care services, from the time of insurance 
eligibility until dropout o death, which includes inpatient claims, outpatient claims, and 
prescription drug usage. In addition, to obtain the census tract socioeconomic information, KCR 
data were linked with the American Community Survey (ACS) 2007-2011 census tract and zip 
code files by census tract codes. These files were used to derive education level and below 
poverty percentage. 
 
Study Population 
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A total of 12792 patients with invasive primary breast cancer and aged 20 or older at the time 
of cancer diagnosis from 2007 to 2011 were collected from the KCR linked data. Patients 
diagnosed through autopsy or death certification have already been excluded from this cohort. 
Subjects who were not continuously enrolled in claims data 12 months before and 13 months 
from cancer diagnosis were then excluded because of possible incomplete claims for medical 
services, which yielded 6054 eligible subjects in the study. 
Depressions 
Depression diagnosis was determined by an algorithm developed by the Centers for Medicare 
and Medicaid Services (CMS) Chronic Conditions Data Warehouse29.Individuals were identified 
with a depression diagnosis if the following International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes shown in inpatient or outpatient visit in claims 
data, including : 296.20, 296.21,296.22,296.23,296.24, 296.25,296.26, 296.30, 296.31, 
296.32,296.33,296.34, 296.35, 296.36, 298.0, 300.4, 309.0, 309.1, or 311.0.  
A baseline period and a follow-up period were used in this cohort study to capture depression 
diagnosis, and the date of cancer diagnosis was designated as the index date. The period of 12 
months prior the cancer diagnosis was defined as the baseline period, and the period included 
the month of cancer diagnosis and 12 months after the cancer diagnosis was designate as the 
follow-up period.  Cancer patients were defined as with pre-diagnosis depression if they were 
with at least one depression diagnosis during the baseline period. Post-diagnosis depression 
was defined as any depression diagnosis recorded during the follow-up period. According to the 
depression diagnosis in baseline and follow-up periods, patients were classified as the following 
four groups: 1. No depression. Patients with no depression diagnosis in both time periods; 2. 
Pre-diagnostic depression only. Patients only had depression diagnosis in the baseline period 
and no depression diagnosis in the follow-up period; 3. Post-diagnostic depression only. 
Patients only had depression diagnosis after cancer diagnosis; 4. Depression in both periods. 
Patients had depression diagnosis in both baseline and follow-up periods. 
Cancer treatment 
Standard treatment for breast cancer was based on claims data as therapy received during the 
follow-up period. Guideline treatment was defined as follows: first all, if patients have hormone 
receptor-positive (estrogen receptor (ER)-positive or progesterone receptor (PR)-positive) 
breast cancer, hormone therapy is included as standard care for all stages. Apart from this, for 
Stage 1 and 2 cancer, modified radical mastectomy or lumpectomy with adjuvant irradiation is 
required. Meanwhile, if the cancer is not hormone receptor-positive, chemotherapy is defined 
as standard care. For stages 3, either begin with neoadjuvant therapy or surgery are 
appropriate, and followed irradiation is required. For stage 4, hormone therapies are used for 
as long as possible before chemotherapy is introduced if the cancer is hormone receptor-
positive. As for patients with hormone-negative cancer, chemotherapy is the primary 
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treatment. These definitions were based on published practice recommendations30. According 
to these definitions, a new indicator variable was created to imply whether appropriate initial 
therapy was received for each subject. Because of the incompleteness of immunity therapy for 
human epidermal growth factor receptor 2(HER2) in KCR linked data, receiving necessary 
immunity therapy was not defined as a criterion when identifying guideline treatment. 
Covariates 
Demographic variables included in the analysis such as age at cancer diagnosis, smoking status, 
race, Appalachian status, marital status, and primary payer were obtained from the KCR data, 
and they were used to categorize subjects. Age at the cancer diagnosis will be classified into 
categorical variables. The ACS 2007-2011 census tract and zip code files provided information 
on the census tract education level and below poverty percentage after being linked with KCR 
data. Survival after cancer diagnosis in the study population was obtained from KCR. Overall 
mortality (death from any causes) was of interest in this study, and the censored date is the 
most recent available date that captures the death information. The Charlson Comorbidity 
Index developed for claims data was utilized to measure comorbidity. Concerning clinical 
variables, the stage at cancer diagnosis, grade, tumor size, and estrogen /progesterone 
receptors status were derived from the KCR data. Cancer treatment information including 
chemotherapy, radiation therapy, hormone therapy, and surgery was obtained from the claims 
data. 
Statistical Analysis 
Patients were classified into four groups based on depression in the baseline and follow-up 
periods, and the comparison of the characteristics and clinical information among these groups 
will be conducted. Proportions were used to describe these categorical variables. A chi-square 
test was used to analyze categorical variables. Multivariable logistic regression will then be 
performed to examine the adjusted association between depression and receiving nonguideline 
cancer treatment, as well as the adjusted association between Appalachian status and receiving 
nonguideline treatment, controlling for age, race, marital status, education level, poverty level, 
primary payer, stage, comorbidity, hormone receptor status. Patients with unknown treatment 
information were excluded from this analysis. Survival rates were first illustrated using the 
Kaplan–Meier method stratified by depression. Multivariate Cox proportional hazards 
regression was then used to estimate adjusted HR. The Cox regression will be conducted by 
adjusting age at diagnosis, smoking status, race, marital status, Appalachian status, primary 
payer, comorbidity, stage, grade, hormone receptor status, her2-neu status, and appropriate 
cancer treatment. Of note, instead of adjusting treatment types such as surgery, 
chemotherapy, and radiation therapy, whether receiving guideline cancer care was controlled 
in this survival analysis. Statistical significances were determined as two-sided P values < .05. 
 
RESULTS  
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Among the 6054 patients, 5212(86.1%) patients were not diagnosed with depression in both 
periods, and 221(3.7%) patients had a depression diagnosis only within one year before the 
cancer diagnosis; meanwhile, 375(6.2%) patients had new recordings of depression after cancer 
diagnosis, and 246(4.1%) women both had depression diagnosis before and after cancer 
diagnosis. Table 1 presents the comparison of demographic characters and clinical information 
among the four groups. Compared with women who have not been diagnosed with depression, 
breast cancer patients who were identified as with depression during the baseline and follow-
up period were statistically significantly more likely to be smokers, younger, from 
Medicare/other public insurance, not in a state of marriage, and with more comorbid diseases. 
Though Appalachian showed a slightly larger percentage of being diagnosed with depression, 
the increase was not statistically significant (p-value=0.99).  
Table 2 displays the results of multivariable logistic regression. In the multivariable logistic 
regression analysis examining the influence of depression and Appalachian status on receiving 
nonguideline cancer treatment, 495 patients with unknown treatment information were 
excluded, and which resulted in 5559 eligible subjects in this analysis. 1770(31.8%) patients 
were defined as not receiving guideline treatment. After adjusting other variables that might 
impact the decision of treatment, no statistically significant association was found between 
depression and receiving nonguideline treatment(p-value=0.282), and patients only had pre-
diagnostic depression showed an increased but nonsignificant odds ratio (OR, 1.38; 95% CI, 
0.99-1.92) in receiving nonguideline treatment compared to patients without depression. 
Patients from Appalachian regions showed an increased association with receiving nonguideline 
treatment (OR, 1.23; 95% CI, 1.02-1.48). 
Survival curves obtained from the Kaplan–Meier method (Figure 1) shows that patients 
diagnosed with depression only within one year before cancer diagnosis had the worst survival. 
Table 3 shows the results from the Cox regression analysis, the adjusted effect of depression on 
survival among breast cancer patients were shown. The association between depression and 
mortality was statistically significant(p-value<.001). Patients with new recordings of depression 
after the cancer diagnosis had a significantly higher risk of death (HR, 1.50; 95% CI, 1.23-1.82). 
However, increased but nonsignificant risks for death were shown in patients diagnosed with 
depression only within one year before cancer diagnosis (HR, 1.23; 95% CI, 0.97-1.56) and 
patients had depression diagnosis in both periods (HR, 1.16; 95% CI, 0.90-1.49). Results also 
illustrated that patients received nonguideline cancer treatment showed a significantly higher 
adjusted hazard ratio (HR, 2.20; 95% CI, 1.95-2.49) than those received guideline treatment.  
 
DISCUSSION 
In this population-based cohort study in Kentucky, the results can be summarized as follows. 
We did not find the support for the hypothesis that a diagnosis of depression was associated 
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with less likelihood of receiving guideline cancer treatment. Newly-diagnosed depression after 
the cancer diagnosis was identified as a negative predictor of survival for breast cancer 
patients. Meanwhile, increased but nonsignificant risks for death were shown in patients 
diagnosed with depression only within one year before cancer diagnosis and patients had 
depression diagnosis in both periods. As for the discrepancy between Appalachian and non-
Appalachian, Appalachian showed increased risks of nonguideline cancer treatment, neither of 
the two increased risks was statistically significant. 
The finding that patients with depression are not a vulnerable group of not receiving guideline 
cancer treatment was not in accordance with previously studies25,26. Compared to Goodwin’s 
focus on a population of patients aged 67 or older25, our results apply to a broader age 
range(>=20 years of age). Meanwhile, using diagnostic of depression in this study rather usage 
of antidepressants26 as a predictor is more accurate when examining the association between 
depression and the outcome because anxiety and pain relief constitutes more than one-quarter 
use of prescribed antidepressants31,32. Though, we assumed that patients with depression 
might show less motivation and a decreased level of self-management, which may lead to a 
poorer commitment to receiving guideline treatment. Our findings indicated that the adjusted 
likelihood of receiving nonguideline treatment in patients with depression was not significantly 
higher than in patients without depression. The discrepancy between receiving guideline 
treatment or not was more determined by socioeconomic factors and clinical variables such as 
stage, comorbidity, and hormone receptor status.  
A five-year observational cohort study has reported that almost half of the early breast cancer 
patients expressed depression, anxiety, or both in the first year after cancer diagnosis, and the 
prevalence dramatically dropped to 25% in the second year33. Therefore, the follow-up period 
of capturing post-diagnosis depression seems feasible in this study. As for pre-diagnosis 
depression, two other population-based studies of breast cancer mortality have demonstrated 
significantly worse overall survival in patients with pre-diagnosis depression20,21. However, this 
association was not found in this study; patients who were diagnosed with depression only 
before cancer diagnosis or had depression both before and after cancer diagnosis did not show 
significantly worse overall survival compared to patients without depression. This might be 
explained by the shorter baseline time to capture prior diagnosis of depression in our study 
compared to two others. One study examined the population of southeast England identified 
pre-diagnosis depression as any diagnosis of depression three years before cancer breast 
diagnosis21. Another study conducted in Denmark even defined pre-diagnosis depression as any 
first-ever psychiatric admission with depressive disorders at age 15 years or older before the 
date of first breast cancer diagnosis20. Thus, compared to these two studies, fewer individuals 
would be determined as with pre-diagnostic depression, and this might result in the different 
results. Importantly, after removing the variable- “appropriate cancer treatment” from the 
multivariate Cox regression model, patients with depression diagnosis only before cancer 
diagnosis showed a significantly worse overall survival (HR=1.41, 95% CI, 1.21-1.74). It implied 
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that patients in this group are more likely to receive nonguideline treatment, which resulted in 
worse survival; however, this relationship was adjusted when including the guideline treatment 
variable in the Multivariate Cox model. Thus, we found a nonsignificant association between 
pre-diagnostic only and mortality.  
Patients with newly diagnosed depression were found significantly more likely to have worse 
overall survivals. However, there’s no significant difference between patients without 
depression and patients with depression both before and after a cancer diagnosis. This could be 
interpreted that persistent depression diagnosis represents patients with depression were 
recognized and managed. Thus, earlier detection and well-management of depression may 
have had a more positive influence on health behaviors and compliance with cancer treatment. 
Davis’s report also reported a similar conclusion that patients with metastatic breast cancer 
with decreased depressive symptoms in the first year were more likely to have a longer 
subsequent survival34; thus, we may infer that effective treatment of depression improves 
survival in patients with breast cancer, though further research is needed to confirm this 
assumption. 
A study has shown that women with depression from poverty regions than all breast cancer had 
a higher risk of experiencing depression21; besides, adjuvant endocrine therapy adherence and 
persistence was lower in Appalachia regions compared to national level35. Therefore, we 
hypothesized that breast cancer patients residing in Appalachian areas would present higher 
risks of experiencing depression and receiving nonguideline breast cancer treatment. However, 
no significant difference of developing depression between Appalachian and non-Appalachian 
was found in this study. It was likely was due to the lower presence of community mental 
health clinics, and the lager shortage of mental health-care in Appalachian areas36, breast 
cancer patients living in these areas had less access to psychiatry visits and thus were less likely 
to be diagnosed with depression.  
The main advantages of the present study included larger sample size than most of the studies 
in this field, same classification system, the completeness and sound quality of the KCR registry 
data and administrative claims data, and the relatively comprehensive controlling for survival-
related prognostic covariates. Especially for variables like smoking status, ER status, PR status, 
and HER2 status, though they are highly associated with breast cancer survival, they were 
seldom involved in previous studies. Of note, introducing the combination of depression in two 
periods (before and after the cancer diagnosis) to classify patients could distinguish the effect 
of thecancer diagnosis on developing depression, which has been seldom used in this field. As 
for the limitations of this study, first of all, the exclusion of patients without continuous 
enrollment in claims data may result in the miss of valuable information. It is more often that 
women with a lower socioeconomic status were more likely to drop from insurance than the 
general female population37, and low socioeconomic has consistently shown a relationship with 
significantly worse survival in breast cancer patients7.   
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In conclusion, among women with primary invasive breast cancer in Kentucky, we found that 
patients from Appalachian had a statistically significantly higher risk for not receiving guideline 
cancer treatment, and patients only with a pre-diagnostic showed an increase but 
nonsignificant increased risk of receiving nonguideline treatment. The nonguideline cancer 
treatment would result in worse survival among these breast cancer patients, which indicates 
that improvement of breast cancer guideline treatment in this group of patients may increase 
the post-diagnostic survival in these groups. Besides, newly diagnosed depression after a cancer 
diagnosis had a significant association with adverse overall mortality. As a result, introducing 
social support, psychological interventions, or depression screening for breast cancer patients 
after cancer diagnosis especially within one year after cancer diagnosis were recommended. 
The target population is patients who are with lower socioeconomic status, living alone, in 
younger age groups, benefiting from Medicaid or other public insurance, and presenting more 
comorbidities. As for the different likelihood of receiving nonguideline cancer treatment 
between Appalachian and non-Appalachian breast cancer patients, improvement of medical 
services should be promoted for Appalachian patients, which will lead to better survival in this 
underserved group. 
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